Clene Q2 2026: Going Concern Warning, Material Weaknesses, and $21.5M Loss
CLNN sits 18% above its 52-week low of $3.5.
Summary
Clene's Q2 2026 10-Q discloses a going concern warning, material weaknesses in internal controls, and a $21.5 million net loss driven by non-cash fair value adjustments.
Key Events · Earnings and Guidance · CLNN
-
Going Concern Warning
Company expects insufficient cash within 12 months unless additional financing is obtained. Cash and cash equivalents were $9.7 million as of June 30, 2026.
-
Material Weaknesses in Internal Controls
Management identified material weaknesses in internal control over financial reporting, including deficiencies in control environment, reconciliations, and IT general controls.
-
Net Loss Driven by Non-Cash Fair Value Changes
Net loss of $21.5 million for six months ended June 30, 2026, included $14.1 million in non-cash losses from changes in fair value of warrant and derivative liabilities, driven by stock price changes.
-
Capital Raises in H1 2026
Raised $13.0 million in gross proceeds from registered direct offerings during the six months ended June 30, 2026, including a $7.0 million offering in May 2026.
Analysis · CLNN · Life Sciences
Clene's Q2 2026 report reveals a going concern warning — the company expects to run out of cash within 12 months without new financing. The net loss of $21.5 million was driven by $14.1 million in non-cash fair value losses on warrant and derivative liabilities, which are mark-to-market adjustments tied to the stock price, not cash outflows. The company also disclosed material weaknesses in internal controls, adding governance risk. Cash stands at $9.7 million, and the company raised $13 million in the first half of 2026, but that may not be enough to sustain operations.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 45% of the 300 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.26%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLNN was trading at $4.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.5M. The 52-week trading range was $3.50 to $13.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.